Sandoz (until 2023 spin-off)
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Richard_Saynor
|
| gptkbp:countryOfOrigin |
gptkb:Switzerland
|
| gptkbp:focus |
Affordable medicines
|
| gptkbp:founded |
1886
|
| gptkbp:headquartersLocation |
gptkb:Holzkirchen,_Germany
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:mergedInto |
gptkb:Novartis_(1996)
|
| gptkbp:notableEvent |
Spun off from Novartis in 2023
|
| gptkbp:notableProduct |
gptkb:Penicillin
LSD (historically) |
| gptkbp:numberOfEmployees |
~22,000 (2022)
|
| gptkbp:parentCompany |
gptkb:Novartis
|
| gptkbp:predecessor |
gptkb:Sandoz_AG
|
| gptkbp:products |
Generic drugs
Biosimilars |
| gptkbp:publiclyTraded |
No (until 2023 spin-off)
|
| gptkbp:spinOff |
2023
|
| gptkbp:website |
https://www.sandoz.com/
|
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sandoz (until 2023 spin-off)
|